# New paper in eLife

I never thought this would ever be finished but it’s out. We hedge in the paper but my bet is that MYC is a facilitator of an accelerator essential for gene transcription.

# Dissecting transcriptional amplification by MYC

eLife 2020;9:e52483

Zuqin Nie, Chunhua Guo, Subhendu K Das, Carson C Chow, Eric Batchelor, S Stoney Simons Jr, David Levens

## Abstract

Supraphysiological MYC levels are oncogenic. Originally considered a typical transcription factor recruited to E-boxes (CACGTG), another theory posits MYC a global amplifier increasing output at all active promoters. Both models rest on large-scale genome-wide ”-omics’. Because the assumptions, statistical parameter and model choice dictates the ‘-omic’ results, whether MYC is a general or specific transcription factor remains controversial. Therefore, an orthogonal series of experiments interrogated MYC’s effect on the expression of synthetic reporters. Dose-dependently, MYC increased output at minimal promoters with or without an E-box. Driving minimal promoters with exogenous (glucocorticoid receptor) or synthetic transcription factors made expression more MYC-responsive, effectively increasing MYC-amplifier gain. Mutations of conserved MYC-Box regions I and II impaired amplification, whereas MYC-box III mutations delivered higher reporter output indicating that MBIII limits over-amplification. Kinetic theory and experiments indicate that MYC activates at least two steps in the transcription-cycle to explain the non-linear amplification of transcription that is essential for global, supraphysiological transcription in cancer.

# How to make a fast but bad COVID-19 test good

Among the myriad of problems we are having with the COVID-19 pandemic, faster testing is one we could actually improve. The standard test for the presence of SARS-CoV-2 virus uses PCR (polymerase chain reaction), which amplifies targeted viral RNA. It is accurate (high specificity) but requires relatively expensive equipment and reagents that are currently in short supply. There are reports of wait times of over a week, which renders a test useless for contact tracing.

An alternative to PCR is an antigen test that tests for the presence of protein fragments associated with COVID-19. These tests can in principle be very cheap and fast, and could even be administered on paper strips. They are generally much more unreliable than PCR and thus have not been widely adopted. However, as I show below by applying the test multiple times, the noise can be suppressed and a poor test can be made arbitrarily good.

The performance of binary tests are usually gauged by two quantities – sensitivity and specificity. Sensitivity is the probability that you test positive (i.e are infected) given that you actually are positive (true positive rate). Specificity is the probability that you test negative if you actually are negative (true negative rate). For a pandemic, sensitivity is more important than specificity because missing someone who is infected means you could put lots of people at risk while a false positive just means the person falsely testing positive is inconvenienced (provided they cooperatively self-isolate). Current PCR tests have very high specificity but relatively low sensitivity (as low as 0.7) and since we don’t have enough capability to retest, a lot of tested infected people could be escaping detection.

The way to make any test have arbitrarily high sensitivity and specificity is to apply it multiple times and take some sort of average. However, you want to do this with the fewest number of applications. Suppose we administer $n$ tests on the same subject, the probability of getting more than $k$ positive tests if the person is positive is $Q(k,n,q) = 1 - CDF(k|n,q)$, where $CDF$ is the cumulative distribution function of the Binomial distribution (i.e. probability that the number of Binomial distributed events is less than or equal to $k$). If the person is negative then the probability of  $k$ or fewer positives is $R(k,n,r) = CDF(k|n,1-r)$. We thus want to find the minimal $n$ given a desired sensitivity and specificity, $q'$ and $r'$. This means that we need to solve the constrained optimization problem: find the minimal $n$ under the constraint that $k < n$, $Q(k,n,q) = \ge q'$ and $R(k,n,r)\ge r'$. $Q$ decreases and $R$ increases with increasing $k$ and vice versa for $n$. We can easily solve this problem by sequentially increasing $n$ and scanning through $k$ until the two constraints are met. I’ve included the Julia code to do this below.  For example, starting with a test with sensitivity .7 and specificity 1 (like a PCR test), you can create a new test with greater than .95 sensitivity and specificity, by administering the test 3 times and looking for a single positive test. However, if the specificity drops to .7 then you would need to find more than 8 positives out of 17 applications to be 95% sure you have COVID-19.

using Distributions

function Q(k,n,q)
d = Binomial(n,q)
return 1 – cdf(d,k)
end

function R(k,n,r)
d = Binomial(n,1-r)
return cdf(d,k)
end

function optimizetest(q,r,qp=.95,rp=.95)

nout = 0
kout = 0

for n in 1:100
for k in 0:n-1
println(R(k,n,r),” “,Q(k,n,q))
if R(k,n,r) >= rp && Q(k,n,q) >= qp
kout=k
nout=n
break
end
end
if nout > 0
break
end
end

return nout, kout
end

# Slides for Covid-19 talk

Here are my slides for my recent COVID-19 talk at the Centre for Applied Mathematics in BioScience and Medicine (CAMBAM). It’s an updated version of the one I gave to the FDA.

# Remember the ventilator

According to our model, the global death rate due to Covid-19 is around 1 percent for all infected (including unreported). However, if it were not for modern medicine and in particular the ventilator, the death rate would be much higher. Additionally, the pandemic first raged in the developed world and is only recently engulfing parts of the world where medical care is not as ubiquitous although this may be mitigated by a younger populace in those places. The delay between the appearance of a Covid-19 case and deaths is also fairly long; our model predicts a mean of over 50 days. So the lower US death rate compared to April could change in a month or two when the effects of the recent surges in the US south and west are finally felt.